These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 17345816)

  • 1. [Efficacy and safety of peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C virus infection].
    Delić D
    Med Pregl; 2006; 59(9-10):415-9. PubMed ID: 17345816
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Peginterferon alfa-2a plus ribavirin is more effective than peginterferon alfa-2b plus ribavirin for treating chronic hepatitis C virus infection.
    Ascione A; De Luca M; Tartaglione MT; Lampasi F; Di Costanzo GG; Lanza AG; Picciotto FP; Marino-Marsilia G; Fontanella L; Leandro G
    Gastroenterology; 2010 Jan; 138(1):116-22. PubMed ID: 19852964
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Peginterferon alfa-2a (40KD) (PEGASYS) plus ribavirin (COPEGUS) in retreatment of chronic hepatitis C patients, nonresponders and relapsers to previous conventional interferon plus ribavirin therapy.
    Parise E; Cheinquer H; Crespo D; Meirelles A; Martinelli A; Sette H; Gallizi J; Silva R; Lacet C; Correa E; Cotrim H; Fonseca J; Paraná R; Spinelli V; Amorim W; Tatsch F; Pessoa M;
    Braz J Infect Dis; 2006 Feb; 10(1):11-6. PubMed ID: 16767309
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of pegylated interferon alfa-2b and ribavirin combination therapy versus pegylated interferon monotherapy in hemodialysis patients: a comparison of 2 sequentially treated cohorts.
    Tseng PL; Chen TC; Chien YS; Hung CH; Yen YH; Chang KC; Tsai MC; Lin MT; Lee CT; Shen CH; Hu TH
    Am J Kidney Dis; 2013 Oct; 62(4):789-95. PubMed ID: 23746377
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trial.
    Manns M; Marcellin P; Poordad F; de Araujo ES; Buti M; Horsmans Y; Janczewska E; Villamil F; Scott J; Peeters M; Lenz O; Ouwerkerk-Mahadevan S; De La Rosa G; Kalmeijer R; Sinha R; Beumont-Mauviel M
    Lancet; 2014 Aug; 384(9941):414-26. PubMed ID: 24907224
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial.
    Jacobson IM; Dore GJ; Foster GR; Fried MW; Radu M; Rafalsky VV; Moroz L; Craxi A; Peeters M; Lenz O; Ouwerkerk-Mahadevan S; De La Rosa G; Kalmeijer R; Scott J; Sinha R; Beumont-Mauviel M
    Lancet; 2014 Aug; 384(9941):403-13. PubMed ID: 24907225
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improved virologic response in chronic hepatitis C genotype 4 treated with nitazoxanide, peginterferon, and ribavirin.
    Rossignol JF; Elfert A; El-Gohary Y; Keeffe EB
    Gastroenterology; 2009 Mar; 136(3):856-62. PubMed ID: 19135998
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of danoprevir-ritonavir plus peginterferon alfa-2a-ribavirin in hepatitis C virus genotype 1 prior null responders.
    Gane EJ; Rouzier R; Wiercinska-Drapalo A; Larrey DG; Morcos PN; Brennan BJ; Le Pogam S; Nájera I; Petric R; Tran JQ; Kulkarni R; Zhang Y; Smith P; Yetzer ES; Shulman NS
    Antimicrob Agents Chemother; 2014; 58(2):1136-45. PubMed ID: 24295986
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antiviral effects and safety of telaprevir, peginterferon alfa-2a, and ribavirin for 28 days in hepatitis C patients.
    Lawitz E; Rodriguez-Torres M; Muir AJ; Kieffer TL; McNair L; Khunvichai A; McHutchison JG
    J Hepatol; 2008 Aug; 49(2):163-9. PubMed ID: 18486984
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment.
    Shiffman ML; Di Bisceglie AM; Lindsay KL; Morishima C; Wright EC; Everson GT; Lok AS; Morgan TR; Bonkovsky HL; Lee WM; Dienstag JL; Ghany MG; Goodman ZD; Everhart JE;
    Gastroenterology; 2004 Apr; 126(4):1015-23; discussion 947. PubMed ID: 15057741
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Peginterferon alfa-2a (40 kilodaltons) and ribavirin in patients with chronic hepatitis C and normal aminotransferase levels.
    Zeuzem S; Diago M; Gane E; Reddy KR; Pockros P; Prati D; Shiffman M; Farci P; Gitlin N; O'Brien CB; Lamour F; Lardelli P;
    Gastroenterology; 2004 Dec; 127(6):1724-32. PubMed ID: 15578510
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Peginterferon alfa-2a and ribavirin for chronic hepatitis C genotype 1 infections in black patients: safety, tolerability and impact on sustained virologic response.
    Howell CD; Jeffers LS; Cassidy W; Reddy KR; Hu S; Lee JS
    J Viral Hepat; 2006 Jun; 13(6):371-6. PubMed ID: 16842439
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Induction pegylated interferon alfa-2a and high dose ribavirin do not increase SVR in heavy patients with HCV genotype 1 and high viral loads.
    Reddy KR; Shiffman ML; Rodriguez-Torres M; Cheinquer H; Abdurakhmanov D; Bakulin I; Morozov V; Silva GF; Geyvandova N; Stanciu C; Rabbia M; McKenna M; Thommes JA; Harrison SA;
    Gastroenterology; 2010 Dec; 139(6):1972-83. PubMed ID: 20816836
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Peginterferon alfa-2a plus ribavirin for initial treatment of chronic hepatitis C in Korea].
    Lee H; Choi MS; Paik SW; Kim JH; Kim DY; Lee JH; Koh KC; Yoo BC; Rhee JC; Song SM
    Korean J Hepatol; 2006 Mar; 12(1):31-40. PubMed ID: 16565604
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Efficacy and safety of peginterferon alfa-2a and ribavirin treatment of chronic hepatitis C in the Republic of Serbia].
    Božić M; Bojović K; Fabri M; Nožić D; Trkulja B; Milošević I
    Srp Arh Celok Lek; 2012; 140(7-8):448-55. PubMed ID: 23092029
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of peginterferon α-2a (40 KD) plus ribavirin in treatment-naive chronic hepatitis C patients in Central and Eastern Europe.
    Urbanek P; Oltman M; Ivanovski L; Rehák V; Messinger D; Tietz A; Husa P
    Eur J Gastroenterol Hepatol; 2011 Nov; 23(11):1004-10. PubMed ID: 21904204
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A preliminary study on the efficacy and influencing factors of interferon for the treatment of genotype 1 chronic hepatitis C with different dosage forms.
    Ma P; Yang JM; Hou W; Song SD; Wang L; Lu W
    Eur J Gastroenterol Hepatol; 2013 May; 25(5):601-5. PubMed ID: 23263720
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Randomized controlled trial of danoprevir plus peginterferon alfa-2a and ribavirin in treatment-naïve patients with hepatitis C virus genotype 1 infection.
    Marcellin P; Cooper C; Balart L; Larrey D; Box T; Yoshida E; Lawitz E; Buggisch P; Ferenci P; Weltman M; Labriola-Tompkins E; Le Pogam S; Nájera I; Thomas D; Hooper G; Shulman NS; Zhang Y; Navarro MT; Lim CY; Brunda M; Terrault NA; Yetzer ES
    Gastroenterology; 2013 Oct; 145(4):790-800.e3. PubMed ID: 23811112
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Daclatasvir plus peginterferon and ribavirin is noninferior to peginterferon and ribavirin alone, and reduces the duration of treatment for HCV genotype 2 or 3 infection.
    Dore GJ; Lawitz E; Hézode C; Shafran SD; Ramji A; Tatum HA; Taliani G; Tran A; Brunetto MR; Zaltron S; Strasser SI; Weis N; Ghesquiere W; Lee SS; Larrey D; Pol S; Harley H; George J; Fung SK; de Lédinghen V; Hagens P; McPhee F; Hernandez D; Cohen D; Cooney E; Noviello S; Hughes EA
    Gastroenterology; 2015 Feb; 148(2):355-366.e1. PubMed ID: 25311593
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Peginterferon alfa-2a and peginterferon alfa-2b combined with ribavirin in patients with genotype 1 chronic hepatitis C: results of a prospective single-centre study.
    Berak H; Laskus T; Kołakowska-Rządzka A; Wasilewski M; Stańczak JJ; Bardadin K; Walewska-Zielecka B; Horban A
    Adv Med Sci; 2014 Sep; 59(2):261-5. PubMed ID: 25117425
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.